tetano
Editor, Senior Moderator
Mult Scler Relat Disord. 2020 May 8;42:102182. doi: 10.1016/j.msard.2020.102182. [Epub ahead of print]
A fine balance: Immunosuppression and immunotherapy in a patient with multiple sclerosis and COVID-19.
Valencia-Sanchez C[SUP]1[/SUP], Wingerchuk DM[SUP]2[/SUP].
Author information
Abstract
BACKGROUND:
Treatment decisions in patients with multiple sclerosis (MS) during the coronavirus disease 2019 (COVID-19) pandemic are challenging. It is not known whether and how various disease modifying therapies, especially immunosuppressive drugs, affect COVID-19 risk and disease course.
METHODS:
Case report RESULTS: We report a fingolimod-treated MS patient who developed severe COVID-19 but recovered after treatment with tocilizumab.
CONCLUSION:
This report suggests that a brief course of tocilizumab for the treatment of severe COVID-19 may be effective while not aggravating pre-existing MS.
Copyright ? 2020 Elsevier B.V. All rights reserved.
KEYWORDS:
COVID-19; Fingolimod; Multiple sclerosis; Tocilizumab
PMID:32416330DOI:10.1016/j.msard.2020.102182
A fine balance: Immunosuppression and immunotherapy in a patient with multiple sclerosis and COVID-19.
Valencia-Sanchez C[SUP]1[/SUP], Wingerchuk DM[SUP]2[/SUP].
Author information
Abstract
BACKGROUND:
Treatment decisions in patients with multiple sclerosis (MS) during the coronavirus disease 2019 (COVID-19) pandemic are challenging. It is not known whether and how various disease modifying therapies, especially immunosuppressive drugs, affect COVID-19 risk and disease course.
METHODS:
Case report RESULTS: We report a fingolimod-treated MS patient who developed severe COVID-19 but recovered after treatment with tocilizumab.
CONCLUSION:
This report suggests that a brief course of tocilizumab for the treatment of severe COVID-19 may be effective while not aggravating pre-existing MS.
Copyright ? 2020 Elsevier B.V. All rights reserved.
KEYWORDS:
COVID-19; Fingolimod; Multiple sclerosis; Tocilizumab
PMID:32416330DOI:10.1016/j.msard.2020.102182